Mutual of America Capital Management LLC Buys 17,922 Shares of Vericel Co. (NASDAQ:VCEL)

Mutual of America Capital Management LLC grew its stake in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 13.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 150,141 shares of the biotechnology company's stock after buying an additional 17,922 shares during the quarter. Mutual of America Capital Management LLC owned 0.30% of Vericel worth $8,244,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Wellington Management Group LLP raised its position in shares of Vericel by 214.0% during the 3rd quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company's stock valued at $24,837,000 after buying an additional 400,667 shares in the last quarter. Stifel Financial Corp raised its position in shares of Vericel by 40.0% during the 3rd quarter. Stifel Financial Corp now owns 28,073 shares of the biotechnology company's stock valued at $1,186,000 after buying an additional 8,020 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Vericel by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company's stock valued at $48,768,000 after buying an additional 9,613 shares in the last quarter. Louisiana State Employees Retirement System raised its position in shares of Vericel by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company's stock valued at $1,312,000 after buying an additional 200 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Vericel during the 3rd quarter valued at $563,000.

Remove Ads

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on VCEL. BTIG Research raised their price objective on shares of Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Truist Financial restated a "buy" rating and set a $61.00 price objective (down previously from $67.00) on shares of Vericel in a research report on Monday. StockNews.com cut shares of Vericel from a "hold" rating to a "sell" rating in a research report on Friday, February 28th. Canaccord Genuity Group lifted their target price on shares of Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Finally, Stephens reiterated an "overweight" rating and issued a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $62.29.

Vericel Trading Down 3.9 %

Shares of VCEL stock traded down $2.02 during mid-day trading on Thursday, reaching $49.51. The stock had a trading volume of 97,549 shares, compared to its average volume of 413,424. The stock's 50-day moving average price is $56.81 and its two-hundred day moving average price is $51.93. Vericel Co. has a 52-week low of $39.12 and a 52-week high of $63.00. The firm has a market capitalization of $2.44 billion, a PE ratio of 824.40 and a beta of 1.72.

Insider Buying and Selling at Vericel

In other Vericel news, insider Jonathan Siegal sold 3,908 shares of the business's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total value of $242,256.92. Following the transaction, the insider now owns 1,206 shares in the company, valued at approximately $74,759.94. The trade was a 76.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the transaction, the director now owns 26,595 shares in the company, valued at $1,662,187.50. The trade was a 8.59 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,500 shares of company stock worth $466,200. 5.20% of the stock is currently owned by company insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.